1.
Sublingual or subcutaneous immunotherapy for allergic rhinitis?
Journal of allergy and clinical immunology, 2016-02, Vol.137 (2), p.350-350

2.
Allergen immunotherapy: A practice parameter third update
by Cox, Linda, MD
Journal of allergy and clinical immunology, 2010, Vol.127 (1), p.S1-S55

3.
Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial...
by Demoly, Pascal, MD, PhD
Journal of allergy and clinical immunology, 2015, Vol.137 (2), p.444-451.e8

4.
Coinhibitory Pathways in Immunotherapy for Cancer
by Baumeister, Susanne H
Annual review of immunology, 2016-05-20, Vol.34 (1), p.539-573

5.
Noninjection routes for immunotherapy
by Canonica, Giorgio Walter
Journal of allergy and clinical immunology, 2003-03, Vol.111 (3), p.437-448

6.
Food allergen immunotherapy: Current status and prospects for the future
by Wood, Robert A., MD
Journal of allergy and clinical immunology, 2016, Vol.137 (4), p.973-982

7.
Future therapies for food allergies
by Nowak-Węgrzyn, Anna, MD
Journal of allergy and clinical immunology, 2011, Vol.127 (3), p.558-573

8.

9.
Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial
by Nolte, Hendrik, MD, PhD
Journal of allergy and clinical immunology, 2016, Vol.138 (6), p.1631-1638

10.
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
by Chalabi, Myriam
Nature medicine, 2020-04, Vol.26 (4), p.566-576

11.
Efficacy of allergen-specific immunotherapy for atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials
by Bae, Jung Min, MD
Journal of allergy and clinical immunology, 2013, Vol.132 (1), p.110-117

12.
Efficacy and safety of sublingual tablets of house dust mite allergen extracts: Results of a dose-ranging study in an environmental exposure chamber
by Roux, Michel, MD
Journal of allergy and clinical immunology, 2016, Vol.138 (2), p.451-458.e5

13.
Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy
by Kiel, Menno A., MD, MSc
Journal of allergy and clinical immunology, 2013, Vol.132 (2), p.353-360.e2

14.
Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite–induced allergic rhinitis
by Okubo, Kimihiro, MD, PhD
Journal of allergy and clinical immunology, 2016, Vol.139 (6), p.1840-1848.e10

15.
Emerging trends in the immunotherapy of pancreatic cancer
by Banerjee, Kasturi
Cancer letters, 2018-03-28, Vol.417, p.35-46

16.
Sublingual grass and ragweed immunotherapy: Clinical considerations—a PRACTALL consensus report
by Li, James T., MD, PhD
Journal of allergy and clinical immunology, 2015, Vol.137 (2), p.369-376

17.
Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber
by Nolte, Hendrik, MD, PhD
Journal of allergy and clinical immunology, 2015, Vol.135 (6), p.1494-1501.e6

18.
Sublingual immunotherapy: World Allergy Organization position paper 2013 update
by Canonica, Giorgio Walter
The World Allergy Organization journal, 2014-03-28, Vol.7 (1), p.6-6

19.
Basophil expression of diamine oxidase: A novel biomarker of allergen immunotherapy response
by Shamji, Mohamed H., PhD
Journal of allergy and clinical immunology, 2014, Vol.135 (4), p.913-921.e9

20.
Immunotherapy holds the key to cancer treatment and prevention in Constitutional Mismatch Repair Deficiency (CMMRD) syndrome
by Westdorp, Harm
Cancer letters, 2017, Vol.403, p.159-164
